Evaluating Treatment Outcomes for Teens Experiencing Suicidal Thoughts
Our research team developed a protocol funded by a PCORI research award to explore treatment outcomes for adolescents experiencing suicidal thoughts. Cincinnati Children’s collaborates with Nationwide Children’s in Columbus, UT Southwestern in Dallas, and Northwell Health in New York. START, Suicide Treatment Alternatives for Teens, seeks to build an understanding of the standard of care for suicidal thoughts by comparing inpatient treatment with the emerging intervention of outpatient crisis intervention clinics, such as the Bridge Clinic at Cincinnati Children's. Eligible patients are 12-18 years of age who present with a chief complaint of suicidal thoughts. After enrollment, we follow patients for six months and complete surveys every two weeks to evaluate treatment outcomes and safety. The emergence of telehealth as a primary source of services led the research team to identify a need to explore the safety and efficacy of this treatment. During the pandemic, the research team received an award for additional funding for an adjunct protocol to explore treatment outcomes for Telehealth Crisis Intervention Services in addition to inpatient treatment and outpatient crisis intervention clinics.
Next-generation Treatment Studies in Fragile X Syndrome
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism worldwide. Division of Psychiatry faculty Craig Erickson, MD, Kelli Dominick, MD, PhD, Martine Lamy, MD, PhD; and Ernest Pedapati, MD, from both the Divisions of Psychiatry and Neurology, along with Division of Developmental and Behavior Pediatrics member Lauren Schmitt, PhD; Division of Neurology member Christina Gross, PhD; and Division of Behavioral Medicine and Clinical Psychology members Rebecca Shaffer, PsyD, Meredith Will, PsyD, and Elizabeth Smith, PhD, are spearheading a nationwide collaborative to understand brain mechanisms and pioneer new treatments in FXS. Individuals with FXS suffer from heightened irritation from sounds and other sensory experiences believed caused by heightened neuronal excitability. By studying how the FXS brain responds to sensory inputs, we may better understand how the FXS brain may more generally work in autism and intellectual disability.
Cincinnati Children's is the primary human research site for two large NIH-funded research programs with basic science collaborators at UT Southwestern, UCLA and UC Riverside. Collaborators are taking a multilevel, integrated approach that tests mechanisms of sensory neocortical dysfunction in FXS and pharmacological approaches to reduce the deficits. Participants, and their families from around the country, take part in this research program, which includes evaluating brain activity with electroencephalography, eye tracking and novel blood biomarkers. Other neuroimaging programs supported include functional magnetic imaging (fMRI) and near infrared spectroscopy (NIRS). Federal research programs support EEG studies of cognition and transcranial magnetic stimulation-based biomarkers of brain functioning in FXS.
Cincinnati Children's high involvement in translational research includes a multi-electrode fragile X mouse EEG program, a fragile X protein quantification effort, and a gene therapy program. Team involvement in cutting-edge treatment trials for novel pharmaceutical agents for treatment of the core symptoms of FXS, for which no cure exists, includes federally and industry-sponsored clinical trials across pediatric and adult populations. Most recently, Cincinnati Children's announced a next-generation gene therapy program to ultimately address the fundamental deficit in FXS, which is a single dysfunctional gene. With generous divisional investment and institutional support, the FXS program at Cincinnati Children's receives tremendous recognition for research and clinical care. We are well-positioned to make breakthroughs in the field.
